Akero Therapeutics Inc
AKRO54.650USD
0.0000.00%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
4.38BCap. mercado
PérdidaP/E TTM
Más Datos de Akero Therapeutics Inc Compañía
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Información de Akero Therapeutics Inc
Símbolo de cotizaciónAKRO
Nombre de la empresaAkero Therapeutics Inc
Fecha de salida a bolsaJun 20, 2019
Director ejecutivoCheng (Andrew)
Número de empleados63
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 20
Dirección601 Gateway Boulevard, Suite 350
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504876488
Sitio Webhttps://akerotx.com/
Símbolo de cotizaciónAKRO
Fecha de salida a bolsaJun 20, 2019
Director ejecutivoCheng (Andrew)
Ejecutivos de Akero Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-89277.00%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+8266.00%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-200189.00%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Pritchett Henderson
Ms. Jane Pritchett Henderson
Independent Director
Independent Director
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-89277.00%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+8266.00%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-200189.00%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
7.63%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.08%
Wellington Management Company, LLP
5.16%
Otro
67.51%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
7.63%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.08%
Wellington Management Company, LLP
5.16%
Otro
67.51%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
45.16%
Investment Advisor
23.71%
Hedge Fund
18.04%
Private Equity
9.73%
Research Firm
2.95%
Venture Capital
2.56%
Individual Investor
1.08%
Foundation
0.40%
Bank and Trust
0.24%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
504
92.63M
123.44%
-26.38K
2025Q3
532
92.72M
128.44%
-619.25K
2025Q2
513
93.19M
122.60%
+5.80M
2025Q1
481
87.41M
107.62%
+1.72M
2024Q4
438
74.28M
124.07%
+570.22K
2024Q3
432
73.67M
126.17%
-695.38K
2024Q2
416
72.42M
128.65%
-3.01M
2024Q1
408
73.91M
107.89%
+1.88M
2023Q4
389
59.72M
117.03%
+1.94M
2023Q3
376
57.78M
113.32%
+701.00K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
6.28M
7.63%
-458.25K
-6.80%
Sep 30, 2025
General Atlantic LLC
5.73M
6.97%
--
--
Sep 30, 2025
RTW Investments L.P.
5.48M
6.65%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.01M
6.08%
-54.14K
-1.07%
Sep 30, 2025
Wellington Management Company, LLP
4.25M
5.16%
+841.91K
+24.69%
Sep 30, 2025
Deep Track Capital LP
4.00M
4.86%
+958.38K
+31.50%
Sep 30, 2025
Avoro Capital Advisors LLC
3.96M
4.8%
+455.56K
+13.02%
Sep 30, 2025
T. Rowe Price Associates, Inc.
3.72M
4.52%
-702.58K
-15.89%
Sep 30, 2025
State Street Investment Management (US)
3.41M
4.15%
+668.74K
+24.36%
Sep 30, 2025
Bellevue Asset Management AG
2.39M
2.9%
+404.04K
+20.35%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Simplify Propel Opportunities ETF
11.66%
ProShares Merger ETF
2.71%
State Street SPDR S&P Biotech ETF
1.78%
ALPS Medical Breakthroughs ETF
1.75%
AltShares Merger Arbitrage ETF
1.63%
Direxion Daily S&P Biotech Bull 3X Shares
1.1%
ProShares Ultra Nasdaq Biotechnology
0.43%
Invesco Nasdaq Biotechnology ETF
0.42%
iShares Biotechnology ETF
0.34%
Pacer WealthShield ETF
0.28%
Ver más
Simplify Propel Opportunities ETF
Proporción11.66%
ProShares Merger ETF
Proporción2.71%
State Street SPDR S&P Biotech ETF
Proporción1.78%
ALPS Medical Breakthroughs ETF
Proporción1.75%
AltShares Merger Arbitrage ETF
Proporción1.63%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción1.1%
ProShares Ultra Nasdaq Biotechnology
Proporción0.43%
Invesco Nasdaq Biotechnology ETF
Proporción0.42%
iShares Biotechnology ETF
Proporción0.34%
Pacer WealthShield ETF
Proporción0.28%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
